Cargando…
Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and dru...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028134/ https://www.ncbi.nlm.nih.gov/pubmed/36959792 http://dx.doi.org/10.3389/fonc.2023.1071030 |
_version_ | 1784909876686749696 |
---|---|
author | Su, Pengxiao Zhang, Ming Kang, Xin |
author_facet | Su, Pengxiao Zhang, Ming Kang, Xin |
author_sort | Su, Pengxiao |
collection | PubMed |
description | At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms. |
format | Online Article Text |
id | pubmed-10028134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100281342023-03-22 Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges Su, Pengxiao Zhang, Ming Kang, Xin Front Oncol Oncology At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms. Frontiers Media S.A. 2023-03-07 /pmc/articles/PMC10028134/ /pubmed/36959792 http://dx.doi.org/10.3389/fonc.2023.1071030 Text en Copyright © 2023 Su, Zhang and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Su, Pengxiao Zhang, Ming Kang, Xin Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges |
title | Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges |
title_full | Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges |
title_fullStr | Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges |
title_full_unstemmed | Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges |
title_short | Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges |
title_sort | targeting c-met in the treatment of urologic neoplasms: current status and challenges |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028134/ https://www.ncbi.nlm.nih.gov/pubmed/36959792 http://dx.doi.org/10.3389/fonc.2023.1071030 |
work_keys_str_mv | AT supengxiao targetingcmetinthetreatmentofurologicneoplasmscurrentstatusandchallenges AT zhangming targetingcmetinthetreatmentofurologicneoplasmscurrentstatusandchallenges AT kangxin targetingcmetinthetreatmentofurologicneoplasmscurrentstatusandchallenges |